Holen Sie sich die Stockscreener-App
13.31
1.44%
-0.195
Schlusskurs vom Vortag:
$13.51
Offen:
$13.51
24-Stunden-Volumen:
16,611
Relative Volume:
0.16
Marktkapitalisierung:
$457.03M
Einnahmen:
$99.53M
Nettoeinkommen (Verlust:
$-21.57M
KGV:
-20.52
EPS:
-0.6488
Netto-Cashflow:
$-9.84M
1W Leistung:
+6.01%
1M Leistung:
-8.43%
6M Leistung:
-18.66%
1J Leistung:
+23.40%
1-Tages-Spanne:
$13.26
$13.69
1-Wochen-Bereich:
$12.13
$13.53
52-Wochen-Spanne:
$9.22
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.31 | 457.03M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
98.61 | 170.62B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.39 | 119.46B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.48 | 112.95B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.14 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.72 | 50.56B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-18 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2026-07-23 | Eingeleitet | Mizuho | Outperform |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Neuropace Inc For: 22 September - Investing.com India
NeuroPace CFO Patrick Williams Discloses Tax-Related Share Withholding on RSU Vesting - kalkinemedia.com
NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE - MarketBeat
First Light Asset Management, LLC Adds 1.34 Million NeuroPace In - GuruFocus
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
First Light Asset Management LLC Boosts Stake in NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace Inc. (NPCE) Eases 1.76% to $14.50 as Shares Sit Mid-Range Between Support and ResistanceVolume Gap - siam.in
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com India
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com Canada
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com UK
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com India
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
Wells Fargo conference to feature NeuroPace fireside chat Sept. 8 - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayGeographic Revenue Trends - dars.gov.et
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseNHNL Ratio - dars.gov.et
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayWave Equality - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayQuality ETF - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Yahoo Finance
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MARTHA J MORRELL | Officer |
Dec 15 '25 |
Proposed Sale |
16.19 |
25,000 |
404,750 |
0 |
9.64%
5.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):